| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 148, 1375-1380, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
L Cheng, M Nagabhushan, TP Pretlow, SB Amini and TG Pretlow
Institute of Pathology, Case Western Reserve University Medical Center, Cleveland, Ohio 44106, USA.
Immunohistochemical studies have suggested that E-cadherin may be a useful prognostic marker in prostate cancer. Previous studies have depended on cryostat sections of tissues selected grossly. Many prostate cancers, even when extensive, are not visible grossly; many others cannot be demarcated sharply grossly. The wide applicability of prognostic markers after total prostatectomy will depend upon methods that can be applied to tissue selected based upon the histopathological examination of the entire prostate. Our purpose was to investigate the possibility that E-cadherin could be demonstrated in paraffin-embedded whole prostates and metastatic prostate cancer. Microwaving in citrate buffer was the best of five methods tested for the demonstration of E- cadherin in paraffin-embedded prostate and was used to investigate 53 primary prostate cancers from 44 patients and lymph node metastases from 14 patients. Metastases of prostate cancer to lymph nodes expressed less (P = 0.008) E-cadherin than primary prostate cancers. The expression of E-cadherin correlated with the histopathological differentiation (Gleason grade) of primary prostate cancers (P = 0.03, Ptrend = 0.003). The use of monoclonal anti-human E-cadherin (HECD-1) with microwaving in citrate buffer followed by immunoperoxidase staining with heavy metal enhancement for the demonstration of E- cadherin in paraffin-embedded tissue will, for the first time, allow the use of archival tissue for prognostic studies of E-cadherin in prostate cancer and other tissue. Our results are consistent with the hypothesis that aggressive prostate cancers exhibit decreased expression of E-cadherin and demonstrate the feasibility of long-term prognostic studies of this molecule in the usually multiple prostate cancers found in whole, formalin-fixed, paraffin-embedded resected prostates.
This article has been cited by other articles:
![]() |
K. Gravdal, O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7003 - 7011. [Abstract] [Full Text] [PDF] |
||||
![]() |
T L Cibull, T D Jones, L Li, J N Eble, L Ann Baldridge, S R Malott, Y Luo, and L Cheng Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J. Clin. Pathol., March 1, 2006; 59(3): 285 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge, and L. Cheng Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors Clin. Cancer Res., December 1, 2005; 11(23): 8358 - 8363. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cheng, T. D. Jones, R. P. McCarthy, J. N. Eble, M. Wang, G. T. MacLennan, A. Lopez-Beltran, X. J. Yang, M. O. Koch, S. Zhang, et al. Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma Am. J. Pathol., May 1, 2005; 166(5): 1533 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cheng, C.-X. Pan, J.-T. Zhang, S. Zhang, M. S. Kinch, L. Li, L. A. Baldridge, C. Wade, Z. Hu, M. O. Koch, et al. Loss of 14-3-3{sigma} in Prostate Cancer and Its Precursors Clin. Cancer Res., May 1, 2004; 10(9): 3064 - 3068. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Stefansson, H. B. Salvesen, and L. A. Akslen Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1242 - 1252. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-X. Pan, M. S. Kinch, P. A. Kiener, S. Langermann, G. Serrero, L. Sun, J. Corvera, C. J. Sweeney, L. Li, S. Zhang, et al. PC Cell-Derived Growth Factor Expression in Prostatic Intraepithelial Neoplasia and Prostatic Adenocarcinoma Clin. Cancer Res., February 15, 2004; 10(4): 1333 - 1337. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zeng, Z. Hu, M. S. Kinch, C.-X. Pan, D. A. Flockhart, C. Kao, T. A. Gardner, S. Zhang, L. Li, L. A. Baldridge, et al. High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia Am. J. Pathol., December 1, 2003; 163(6): 2271 - 2276. [Abstract] [Full Text] |
||||
![]() |
J. Rios-Doria, K. C. Day, R. Kuefer, M. G. Rashid, A. M. Chinnaiyan, M. A. Rubin, and M. L. Day The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells J. Biol. Chem., January 3, 2003; 278(2): 1372 - 1379. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Rauen, D. Sudilovsky, J. L. Le, K. L. Chew, B. Hann, V. Weinberg, L. D. Schmitt, and F. McCormick Expression of the Coxsackie Adenovirus Receptor in Normal Prostate and in Primary and Metastatic Prostate Carcinoma: Potential Relevance to Gene Therapy Cancer Res., July 1, 2002; 62(13): 3812 - 3818. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikonen, M. Matikainen, N. Mononen, E.-R. Hyytinen, H. J. Helin, S. Tommola, T. L. J. Tammela, E. Pukkala, J. Schleutker, O.-P. Kallioniemi, et al. Association of E-Cadherin Germ-Line Alterations with Prostate Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3465 - 3471. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Rashid, M. G. Sanda, C. J. Vallorosi, J. Rios-Doria, M. A. Rubin, and M. L. Day Posttranslational Truncation and Inactivation of Human E-Cadherin Distinguishes Prostate Cancer from Matched Normal Prostate Cancer Res., January 1, 2001; 61(2): 489 - 492. [Abstract] [Full Text] |
||||
![]() |
S. Kase, K. Sugio, K. Yamazaki, T. Okamoto, T. Yano, and K. Sugimachi Expression of E-cadherin and {beta}-Catenin in Human Non-Small Cell Lung Cancer and the Clinical Significance Clin. Cancer Res., December 1, 2000; 6(12): 4789 - 4796. [Abstract] [Full Text] |
||||
![]() |
R. Thomas, L. D. True, J. A. Bassuk, P. H. Lange, and R. L. Vessella Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression Clin. Cancer Res., March 1, 2000; 6(3): 1140 - 1149. [Abstract] [Full Text] |
||||
![]() |
J. Luo, D. M. Lubaroff, and M. J. C. Hendrix Suppression of Prostate Cancer Invasive Potential and Matrix Metalloproteinase Activity by E-Cadherin Transfection Cancer Res., August 1, 1999; 59(15): 3552 - 3556. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text] |
||||
![]() |
B. Nawrocki, M. Polette, J. Van Hengel, J.-M. Tournier, F. Van Roy, and P. Birembaut Cytoplasmic Redistribution of E-Cadherin-Catenin Adhesion Complex Is Associated with Down-Regulated Tyrosine Phosphorylation of E-Cadherin in Human Bronchopulmonary Carcinomas Am. J. Pathol., November 1, 1998; 153(5): 1521 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. SULZER, M. P. G. LEERS, J. A. van NOORD, E. C. M. BOLLEN, and P. H. M. H. THEUNISSEN Reduced E-Cadherin Expression Is Associated with Increased Lymph Node Metastasis and Unfavorable Prognosis in Non-small Cell Lung Cancer Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1319 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ikeda, T. Monden, T. Kanoh, M. Tsujie, H. Izawa, A. Haba, T. Ohnishi, M. Sekimoto, N. Tomita, H. Shiozaki, et al. Extraction and Analysis of Diagnostically Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections J. Histochem. Cytochem., March 1, 1998; 46(3): 397 - 404. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |